Q2 FY2026 EarningsQ2 FY26 results were significantly impacted by non-cash crypto gains, leading to a major EPS beat of $0.18 vs. -$0.03 expected. A $46.0M unrealized gain on Zcash (ZEC) treasury holdings drove the bottom-line surprise, despite revenue remaining at $0. Operating loss of -$4.7M was slightly wider than the consensus estimate of -$4.6M, while the Leap Therapeutics subsidiary reached a key FDA alignment for Phase 3 clinical trials.